ALT-711_Dosage, benefits & legal status
Also known as alagebrium, alagebrium chloride, ALT711
An anti-ageing molecule from the 1990s that broke sugar-protein crosslinks in rats and disappointed in people.
Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.
What is ALT-711?
Plain language first. The technical label stays, but it never stands alone.Overview
A small molecule, not a peptide, developed to break the crosslinks that stiffen arteries with age. Human trials never delivered, and the company wound down.
Alagebrium (ALT-711) is a thiazolium compound developed as an advanced glycation end-product crosslink breaker, aimed at arterial stiffness, systolic hypertension and diastolic heart failure.
What it's used for
Sold for longevity and arterial stiffness. The compound has a long human trial record, and most of it is disappointing.
How does ALT-711 work?
What it does in the body, and where.The idea behind ALT-711 is one of the cleanest in ageing biology, which is part of why it keeps coming back.
- 01Sugar sticks proteins togetherAdvanced glycation end-products crosslink collagen and stiffen arteries and other tissue over a lifetime.
- 02This molecule was built to cut those linksIn rats it improved vascular function and reduced crosslinking.
- 03Humans are not rats hereThe crosslink types alagebrium acts on matter more in rodents. Phase 2b missed its blood pressure endpoint in 2003, trials were terminated in January 2009, and the sponsor wound down.
A schematic of the compound's mechanism, not a diagnostic image.
What else is it used for?
Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
- Arterial stiffness and blood pressureInvestigational
- Diastolic heart failureEarly research
- General anti-ageing claimsResearch only
At a glance
Four things to know about ALT-711
Evidence
Research only
Category
Longevity and energy
Common vial
Varies
Half-life
Nothing published in humans
How much, and do you cycle it?
The range, and whether you take breaks.Research only, no established pattern. No established patternNo range
No published human study establishes a schedule.
How long does it stay in the body?
The half-life, and where the figure comes from.Nothing published in humansNo figure
You can compare this against the whole library to see where it sits.
What does it cost?
Typical dose and cost, in plain numbers.ALT-711 is not injected
It is taken by mouth in the trials. sold as a solution. No current dose stands. The compound was given by mouth in phase 2 trials that ended in 2009, and the vendor product is a solution with no protocol attached.
ALT-711 starts at $39.99 across 1 vendor.
1 listing, last read Sep 22, 2026. Shipping and card fees are not included.
How do you store it?
Before mixing, and after.Dry powder in the freezer or fridge. Once mixed, fridge, and use within about a month.
Unmixed lyophilized ALT-711 keeps for a long time cold. Once you add water the clock starts: most reconstituted vials hold up for roughly 28 to 30 days at fridge temperature. Keep it out of light, and do not freeze it after mixing.
What are the side effects and cautions?
Known cautions and warnings for this compound.Who should avoid it
- No approved use exists
- Pregnancy
Stop and get help
- Anything unusual, since no current safety monitoring exists for this compound
- Signs of an allergic reaction such as face or throat swelling, hives, or trouble breathing
Common effects
- Not established outside the original trial programme
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is ALT-711 approved?
And where the numbers on this page come from.No. ALT-711 is not approved for any use, anywhere. It is sold labelled for laboratory research only, and there is no legal route to buy it for human use.
- Approval statusResearch only
- RouteBy mouth in the trials. Sold as a solution
- Checked24 September 2026
- DoseFrom research and community reports. No regulator has reviewed this dose.
- Vial sizeFrom what vendors typically list; not a recommendation.
- Sources
What has happened recently
Never approved. All clinical development terminated in January 2009.
You can compare this against the whole library, or read how to check a seller.
What else is like ALT-711?
Others in Longevity and energy, side by side.If you're weighing ALT-711, it's worth reading Vitamin B12, MOTS-c, and Epitalon in the same class.
An anti-ageing molecule from the 1990s that broke sugar-protein crosslinks in rats and disappointed in people.
- Dose
- Research only
- How often
- No established pattern
The vitamin sold in peptide vials, at prices from $20 to $83 for the same thing.
- Dose
- Prescription products are dosed by a clinician
- How often
- Varies by product and by why it is being given
A shot people use for energy, metabolism, and healthy aging.
- Dose
- 5 up to 10 mg per week (start low, increase slowly)
- How often
- 1-3x per week
A longevity peptide taken in short courses for sleep and anti-aging.
- Dose
- 5 up to 10 mg per day (start low, increase slowly)
- How often
- 10-20 day courses
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Sources
- Little WC, et al. Alagebrium chloride (ALT-711) in elderly patients with diastolic heart failure. J Card Fail(2005)One of the phase 2 cardiovascular studies in the Alteon programme.
- Alagebrium development history, including termination of all trials in January 2009(2009)Phase 2b missed its blood pressure endpoint in 2003; the sponsor terminated clinical work in January 2009.
Last reviewed 24 September 2026